Squarepoint’s ADMA Biologics ADMA Stock Holding History

Squarepoint’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Buy	+20,700	New	+$189K	﹤0.01%	4101
2026 Q1	–	Sell	-234,400	Closed	-$4.28M	–	4201
2025 Q4	$4.28M	Sell	234,400 -4,600	-2%	-$77.5K	﹤0.01%	1553
2025 Q3	$3.5M	Sell	239,000 -10,800	-4%	-$185K	﹤0.01%	1683
2025 Q2	$4.55M	Sell	249,800 -40,700	-14%	-$830K	﹤0.01%	1525
2025 Q1	$5.76M	Sell	290,500 -13,700	-5%	-$237K	0.01%	1336
2024 Q4	$5.22M	Buy	+304,200	New	+$5.72M	0.01%	1596

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Squarepoint's ADMA Position: Q2 2026 in Review

Squarepoint increased its ADMA Biologics (ADMA) stake by 330% in Q2 2026, buying an estimated $2.5M and bringing the position to 357,503 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

Squarepoint first reported a position in ADMA in Q2 2018 and has held it in 25 quarters since. The position peaked at $7.1M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Squarepoint held 357,503 shares of ADMA Biologics worth $2.99M as of Q2 2026.
Squarepoint bought 274,277 ADMA Biologics shares in Q2 2026, an estimated $2.5M.
ADMA Biologics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2012 holding.
Squarepoint first reported a position in ADMA Biologics in Q2 2018 and has held it in 25 quarters since.
Squarepoint's ADMA Biologics position peaked at $7.1M in Q3 2024.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.